Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

September 29, 2017

Study Completion Date

September 29, 2017

Conditions
InfluenzaHealthy
Interventions
BIOLOGICAL

FluMist trivalent (2015-2016)

0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.

BIOLOGICAL

FluMist Quadrivalent (2015-2016)

0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.

BIOLOGICAL

FluMist Quadrivalent (2017-2018)

0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.

Trial Locations (12)

13901

Research Site, Binghamton

31405

Research Site, Savannah

40004

Research Site, Bardstown

57049

Research Site, Dakota Dunes

63141

Research Site, St Louis

68134

Research Site, Omaha

68701

Research Site, Norfolk

76104

Research Site, Fort Worth

76904

Research Site, San Angelo

77375

Research Site, Tomball

84088

Research Site, West Jordan

84124

Research Site, Salt Lake City

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

MedImmune LLC

INDUSTRY